Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial

OBJECTIVE: No drug is yet approved to treat the core symptoms of autism spectrum disorder (ASD). Low‐dose suramin was effective in the maternal immune activation and Fragile X mouse models of ASD. The Suramin Autism Treatment‐1 (SAT‐1) trial was a double‐blind, placebo‐controlled, translational pilo...

Descripción completa

Detalles Bibliográficos
Autores principales: Naviaux, Robert K., Curtis, Brooke, Li, Kefeng, Naviaux, Jane C., Bright, A. Taylor, Reiner, Gail E., Westerfield, Marissa, Goh, Suzanne, Alaynick, William A., Wang, Lin, Capparelli, Edmund V., Adams, Cynthia, Sun, Ji, Jain, Sonia, He, Feng, Arellano, Deyna A., Mash, Lisa E., Chukoskie, Leanne, Lincoln, Alan, Townsend, Jeanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497533/
https://www.ncbi.nlm.nih.gov/pubmed/28695149
http://dx.doi.org/10.1002/acn3.424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497533/
https://www.ncbi.nlm.nih.gov/pubmed/28695149
http://dx.doi.org/10.1002/acn3.424

Ejemplares similares